These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2841895)

  • 1. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity.
    Hainsworth JD; Johnson DH; Greco FA
    Ann Intern Med; 1988 Sep; 109(5):364-71. PubMed ID: 2841895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site.
    Hainsworth JD; Greco FA
    Semin Oncol; 1993 Jun; 20(3):279-86. PubMed ID: 8503024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Dial TW; Greco FA
    Am J Clin Oncol; 1988 Apr; 11(2):138-45. PubMed ID: 2451881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
    Hainsworth JD; Johnson DH; Greco FA
    J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Johnson DH; Greco FA
    Semin Oncol; 1992 Apr; 19(2 Suppl 5):54-7; discussion 58. PubMed ID: 1384145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine carcinoma of unknown primary site.
    Spigel DR; Hainsworth JD; Greco FA
    Semin Oncol; 2009 Feb; 36(1):52-9. PubMed ID: 19179188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining.
    Hainsworth JD; Wright EP; Johnson DH; Davis BW; Greco FA
    J Clin Oncol; 1991 Nov; 9(11):1931-8. PubMed ID: 1941051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):116-22. PubMed ID: 2669133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poorly differentiated carcinoma and germ cell tumors.
    Hainsworth JD; Greco FA
    Hematol Oncol Clin North Am; 1991 Dec; 5(6):1223-31. PubMed ID: 1663941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
    Greco FA; Johnson DH; Hainsworth JD
    Semin Oncol; 1992 Dec; 19(6 Suppl 13):14-8. PubMed ID: 1492223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome.
    Greco FA; Vaughn WK; Hainsworth JD
    Ann Intern Med; 1986 Apr; 104(4):547-53. PubMed ID: 3006571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site.
    Hainsworth JD; Lennington WJ; Greco FA
    J Clin Oncol; 2000 Feb; 18(3):632-5. PubMed ID: 10653878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy.
    Greco FA; Hainsworth JD
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):77-82. PubMed ID: 7992071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic management of cancer of unknown primary site by pathological types].
    Fernández Cotarelo MJ; Guerra Vales JM
    Rev Clin Esp; 2009 Oct; 209(9):439-43. PubMed ID: 19852914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: response to chemotherapy and octreotide LAR.
    Tauchmanovà L; Pensabene M; Capuano I; Spagnoletti I; Zeppa P; Del Vecchio S; Mainenti M; De Rosa G; Colao A; Contegiacomo A
    J Endocrinol Invest; 2005 Apr; 28(4):371-8. PubMed ID: 15966513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?
    Shia J; Tang LH; Weiser MR; Brenner B; Adsay NV; Stelow EB; Saltz LB; Qin J; Landmann R; Leonard GD; Dhall D; Temple L; Guillem JG; Paty PB; Kelsen D; Wong WD; Klimstra DS
    Am J Surg Pathol; 2008 May; 32(5):719-31. PubMed ID: 18360283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors.
    Stoyianni A; Pentheroudakis G; Pavlidis N
    Cancer Treat Rev; 2011 Aug; 37(5):358-65. PubMed ID: 21481536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary.
    van der Gaast A; Verwij J; Planting AS; Stoter G; Henzen-Logmans SC
    J Cancer Res Clin Oncol; 1996; 122(3):181-85. PubMed ID: 8601568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metastatic carcinoma of unknown origin].
    Fizazi K; Culine S
    Bull Cancer; 1998 Jul; 85(7):609-17. PubMed ID: 9752267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple bilateral choroidal metastatic tumors from a small-cell neuroendocrine carcinoma of unknown primary site.
    Nicolò M; Piccolino FC; Ghiglione D; Nicolò G; Calabria G
    Eur J Ophthalmol; 2005; 15(1):148-52. PubMed ID: 15751257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.